文献速递胸部肿瘤

西米普利单抗单药一线治疗PD-L1表达50%及以上晚期非小细胞肺癌:EMPOWER-Lung 1五年结局

Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1.
PubMed 文献 · J Thorac Oncol · 2025-03-19

EMPOWER-Lung 1研究5年随访显示,在PD-L1表达≥50%且无EGFR、ALK或ROS1异常的晚期NSCLC患者中,一线西米普利单抗单药较化疗持续显示持久临床获益,中位总生存26.1个月对13.3个月(HR=0.59,95%CI 0.48-0.72),PD-L1≥90%患者获益最大。

要点

  • PD-L1≥50%验证人群(n=565)中,西米普利单抗组中位OS 26.1个月,化疗组13.3个月,HR=0.59。
  • 中位随访59.6个月时,西米普利单抗组5年OS率为29.0%,化疗组为15.0%。
  • 西米普利单抗组≥3级治疗相关不良事件发生率为18.3%,化疗组为39.9%。

核心结论

  • 5年随访时,一线西米普利单抗单药在PD-L1≥50%的晚期NSCLC患者中较化疗持续显示持久临床获益。
  • PD-L1≥90%的患者获得的临床获益最大。

研究设计与样本

  • 3期EMPOWER-Lung 1试验将患者按1:1随机分配至西米普利单抗350 mg静脉给药每3周一次持续2年或研究者选择的化疗。
  • 共712例患者被随机分配至西米普利单抗组(n=357)或化疗组(n=355)。
  • 主要终点为总生存期(OS)和无进展生存期。

主要发现

  • 数据截止日期为2024年1月16日,中位随访时间为59.6个月(四分位距:55.1-66.7个月)。
  • 在PD-L1≥50%验证人群(n=565)中,西米普利单抗组中位OS为26.1个月,化疗组为13.3个月(HR=0.59,95%CI 0.48-0.72)。
  • 该人群中,西米普利单抗组中位PFS为8.1个月,化疗组为5.3个月(HR=0.50,95%CI 0.41-0.61)。
  • 该人群中,西米普利单抗组客观缓解率为46.5%,化疗组为20.6%。
  • 西米普利单抗组5年OS概率为29.0%,化疗组为15.0%;鳞癌和非鳞癌组织学类型均观察到生存获益改善,且西米普利单抗活性随PD-L1表达升高而增强。

关键数值与推荐

  • PD-L1≥50%验证人群(n=565)中位OS:西米普利单抗组26.1个月 vs 化疗组13.3个月(HR=0.59,95%CI 0.48-0.72)。
  • PD-L1≥50%验证人群(n=565)中位PFS:西米普利单抗组8.1个月 vs 化疗组5.3个月(HR=0.50,95%CI 0.41-0.61)。
  • PD-L1≥50%验证人群(n=565)客观缓解率:西米普利单抗组46.5% vs 化疗组20.6%。
  • 5年OS概率:西米普利单抗组29.0% vs 化疗组15.0%。
  • ≥3级治疗相关不良事件发生率:西米普利单抗组18.3% vs 化疗组39.9%。

临床怎么用

  • 对于PD-L1表达≥50%且无EGFR、ALK或ROS1异常的晚期NSCLC患者,一线西米普利单抗单药较化疗持续显示持久临床获益。
  • PD-L1≥90%的患者获得的临床获益最大。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Earlier results from the phase 3 EMPOWER-Lung 1 trial indicated significant survival benefits and a generally acceptable safety profile of first-line cemiplimab monotherapy versus chemotherapy for patients with advanced NSCLC with programmed cell death-ligand 1 (PD-L1) expression in 50% or more tumor cells and no EGFR, ALK, or ROS1 aberrations. Here, we report the five-year outcomes. METHODS: Patients were randomized 1:1 to cemiplimab 350 mg intravenously every three weeks for two years or the investigator's choice of chemotherapy. The primary endpoints were overall survival (OS) and progression-free survival. RESULTS: A total of 712 patients were randomized to cemiplimab (n = 357) or chemotherapy (n = 355). The median duration of follow-up was 59.6 months (interquartile range: 55.1-66.7 months) at the data cutoff (January 16, 2024). In patients with verified 50% or higher PD-L1 (n = 565), median OS was 26.1 months for cemiplimab versus 13.3 months for chemotherapy (hazard ratio = 0.59, 95% confidence interval [CI]: 0.48-0.72); the median progression-free survival was 8.1 months versus 5.3 months (hazard ratio = 0.50, 95% confidence interval: 0.41-0.61); and the objective response rate was 46.5% versus 20.6%. The five-year OS probability was 29.0% for cemiplimab and 15.0% for chemotherapy. Improved survival outcomes were observed with both squamous and nonsquamous histology, and increasing activity of cemiplimab was correlated with higher PD-L1 expression, with the highest PD-L1 expression having the best outcome. The safety profile remains consistent with previous results. Grade 3 or higher treatment-related adverse events occurred in 18.3% of patients for cemiplimab and 39.9% for chemotherapy. CONCLUSIONS: At five-year follow-up, first-line cemiplimab monotherapy continued to show durable clinical benefits versus chemotherapy in patients with advanced NSCLC with 50% or higher PD-L1. Patients with 90% or higher PD-L1 derived the largest clinical benefits.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Kilickap S, Baramidze A, Sezer A, et al. Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1. J Thorac Oncol. 2025. PMID: 40118215. doi:10.1016/j.jtho.2025.03.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。